CMS Seeks Stakeholder Input on Gene Test Reimbursement, Maintains Code Stacking for 2012
June 22, 2011
CMS Seeks Stakeholder Input on Gene Test Reimbursement, Maintains Code Stacking for 2012
"CMS is the decision-maker here regarding fee schedule placement [of genetic tests] and we are pleased they are recognizing the importance … of having stakeholders provide input on the questions they've asked," said David Mongillo, vice president for policy and medical affairs at the American Clinical Laboratory Association.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- CMS Stance on Reimbursement of Multi-Analyte Algorithm Assays Raises Industry Concerns
September 19, 2012 / Pharmacogenomics Reporter - In Information-Gathering Mode, CMS Undecided on Payment Structure for Genetic Tests
July 20, 2011 / Pharmacogenomics Reporter - CMS Issues Pricing for MDx Codes; Labs, Test Developers Still Critical of Rates and Methodology
May 20, 2013 / Pharmacogenomics Reporter - Lab Industry, Pathologists Still at Odds Over Fee Schedule for New Molecular Pathology CPT Codes
July 18, 2012 / Pharmacogenomics Reporter - Palmetto Issuing 'Z-Codes' to Track Molecular Dx Utilization, Gather Data CPT Codes Can't Provide
November 16, 2011 / Pharmacogenomics Reporter